US Pharm. 2013;38(8):6.
Bethesda, MD—The FDA has approved Brisdelle
(paroxetine) to treat moderate-to-severe hot flashes (vasomotor
symptoms) associated with menopause. Hot flashes are very common and
occur in up to 75% of menopausal women. Brisdelle, which contains the
selective serotonin reuptake inhibitor (SSRI) paroxetine, is currently
the only nonhormonal treatment for hot flashes approved by the FDA.
There are a variety of other FDA-approved drugs for this condition, but
all include estrogen. Brisdelle contains 7.5 mg of paroxetine, while
other medications, such as Paxil and Pexeva, use higher doses of
paroxetine and are approved for treating conditions such as depression,
obsessive-compulsive disorder, and anxiety. As with all SSRIs, a boxed
warning about suicidality is included in the Brisdelle label.
To comment on this article, contact email@example.com.